<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270969</url>
  </required_header>
  <id_info>
    <org_study_id>491-17-FB</org_study_id>
    <nct_id>NCT03270969</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women</brief_title>
  <official_title>Pharmacokinetics of Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-exposure Prophylaxis in Transgender Women Receiving Feminizing Hormone Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human immunodeficiency virus (HIV) persists worldwide as an immense health burden among&#xD;
      vulnerable populations. HIV pre-exposure prophylaxis (PrEP) has offered the promise of&#xD;
      limiting the global burden of HIV. The objective of this proposal is to conduct a&#xD;
      pharmacokinetic (PK) study in transgender women to describe the pharmacokinetics of tenofovir&#xD;
      disoproxil fumarate/emtricitabine (TDF/FTC) as PrEP within this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PrEP is a critical component of comprehensive transgender medical care. The proposed&#xD;
      open-label, intensive PK study will inform the pharmacologic impact of combining PrEP and&#xD;
      concurrent feminizing hormone regimens. The investigators hypothesize transgender women will&#xD;
      achieve similar PrEP concentrations compared to the historical controls, and that hormone&#xD;
      concentrations (estrogen and testosterone) will not be affected. The aims of this study are&#xD;
      to (1) to determine if concurrent use of TDF/FTC as PrEP in combination with feminizing&#xD;
      hormones alters the PK of tenofovir (TFV) and FTC and (2) to determine if concurrent use of&#xD;
      PrEP with feminizing hormones alters serum estradiol and testosterone concentrations. To&#xD;
      achieve these aims, this study will enroll transgender women who are receiving either&#xD;
      oral/sublingual or transdermal estradiol with spironolactone. Using intensive PK sampling,&#xD;
      plasma and intracellular TDF/FTC concentrations will be measured after 14 days of oral&#xD;
      TDF/FTC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TFV plasma exposure</measure>
    <time_frame>14 days</time_frame>
    <description>Intensive PK sampling compared to historical controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FTC plasma exposure</measure>
    <time_frame>14 days</time_frame>
    <description>Intensive PK sampling compared to historical controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tenofovir-diphosphate (TFV-DP) intracellular concentrations</measure>
    <time_frame>14 days</time_frame>
    <description>Peripheral blood mononuclear cells (PBMC) concentrations compared to historical control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emtricitabine-triphosphate (FTC-TP) intracellular concentrations</measure>
    <time_frame>14 days</time_frame>
    <description>Peripheral blood mononuclear cells (PBMC) concentrations compared to historical control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TFV maximum plasma concentration (Cmax)</measure>
    <time_frame>14 days</time_frame>
    <description>Cmax of TFV compared to historical control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FTC maximum plasma concentration (Cmax)</measure>
    <time_frame>14 days</time_frame>
    <description>Cmax of FTC compared to historical control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol serum concentrations</measure>
    <time_frame>14 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone serum concentrations</measure>
    <time_frame>14 days</time_frame>
    <description>Before and after intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>TDF/FTC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate/Emtricitabine</intervention_name>
    <description>Participants will receive daily TDF/FTC for 14 days</description>
    <arm_group_label>TDF/FTC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the participant has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          -  Participants who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
          -  Self identify as a transgender woman.&#xD;
&#xD;
          -  Receiving estradiol (oral/sublingual tablets or transdermal patches) with oral&#xD;
             spironolactone for at least 3 months prior to study entry.&#xD;
&#xD;
          -  Serum estradiol level &gt;100 pg/mL.&#xD;
&#xD;
          -  Non-reactive 4th or 5th generation screening test for HIV.&#xD;
&#xD;
          -  Adults (19 years or older).&#xD;
&#xD;
          -  Able to read and speak English to ensure appropriate ability to obtain informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants will not be included in the study if one, or more, of the following&#xD;
             criteria are met:&#xD;
&#xD;
          -  Use of drugs known to be contraindicated with TDF, FTC, estradiol, or spironolactone&#xD;
             within 30 days of study entry. The study team will review all concomitant medications&#xD;
             at screening based on the US Department of Health and Human Services drug interaction&#xD;
             table and the drug product labeling.&#xD;
&#xD;
          -  Use of injectable estradiol (valerate or cypionate).&#xD;
&#xD;
          -  Presence of any active condition or clinically significant disease that, in the&#xD;
             investigator's opinion, would compromise the subject's safety or outcome of the study,&#xD;
             including qualifying for non-occupational post-HIV exposure prophylaxis.&#xD;
&#xD;
          -  Signs or symptoms of acute HIV infection within the last 30 days.&#xD;
&#xD;
          -  Laboratory values obtained within 30 days prior to study entry:&#xD;
&#xD;
          -  Creatinine clearance (CrCl) less than 60 mL/min as estimated by the Cockcroft-Gault&#xD;
             equation.&#xD;
&#xD;
          -  Positive hepatitis B surface antigen and/or hepatitis C antibody.&#xD;
&#xD;
          -  Alanine transaminase (ALT), Aspartate transaminase (AST) or alkaline phosphatase &gt; 5x&#xD;
             the upper limit of normal (ULN).&#xD;
&#xD;
          -  Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
          -  Platelets &lt;50,000/mm3.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>transgender women</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Kimberly Scarsi, PharmD, MS, BCPS-ID,</investigator_full_name>
    <investigator_title>Postdoctoral Research Associate</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

